Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

DOP020: Higher vedolizumab levels are associated with deep remission in patients with Crohn’s Disease and Ulcerative Colitis on maintenance therapy with vedolizumabECCO'17 Barcelona
Year: 2017
Authors: Yarur A.
Patient reported outcomes, Therapeutic drug monotoring, Pharmacokinetics, Treat to tatrget, Vedolizumab
Files: 1
DOP022: Vedolizumab (VDZ) and anti-α treatment effectiveness in patients with IBD treated in Germany: A retrospective chart reviewECCO'17 Barcelona
Year: 2017
Authors: Ehehalt R.
Crohn's disease, Anti-TNF agents,Vedolizumab
Files: 1
DOP024: Vedolizumab clinical and post-marketing safety experience of opportunistic infectionsECCO'17 Barcelona
Year: 2017
Authors: Ng S.
Concomitant infections, Vedolizumab
Files: 1
DOP025: Efficacy of vedolizumab on extraintestinal manifestation in patients with Inflammatory Bowel Disease: A post-hoc analysis of the OBSERV-IBD cohort from the GETAIDECCO'17 Barcelona
Year: 2017
Authors: Tadbiri S.
Vedolizumab, Arthralgia, Perianal disease, other extraintestinal manifestations
Files: 1
DOP027: Long-term efficacy and safety of ustekinumab in refractory Crohn’s Disease patients: A multicenter retrospective experienceECCO'17 Barcelona
Year: 2017
Authors: Wils P.
Crohn's disease, Anti-TNF agents, Ustekinumab
Files: 1
DOP028: Antibodies towards vedolizumab appear from week 2 onwards and disappear upon treatmentECCO'17 Barcelona
Year: 2017
Authors: Bian S.
Anti drug antibodies, Vedolizumab, Immunology
Files: 1
DOP029: Clinical relevance of detecting anti-infliximab antibodies with a drug-tolerant assay: Post-hoc analysis of the taxit trialECCO'17 Barcelona
Year: 2017
Authors: Van Stappen T.
Crohn's disease, Ulcerative colitis, Anti-TNF drug levels, Anti drug antibodies, Therapeutic drug monitoring, Infliximab
Files: 1
DOP031: Subtherapeutic serum infliximab trough levels and complete mucosal healing are associated with sustained clinical remission after infliximab discontinuation in paediatric Crohn’s Disease patientsECCO'17 Barcelona
Year: 2017
Authors: Kang B.
Anti-TNF drug levels, Colonoscopy, Infliximab, Pharmacokinetics, Thiopurines (AZA / MP)
Files: 1
DOP032: Hydrocortisone premedication withdrawal in patients on stable infliximab maintenance: Clinical and pharmacokinetic outcomesECCO'17 Barcelona
Year: 2017
Authors: Tran-Minh M.
Anti-TNF drug levels, Anti-drug antibodies, Anti-TNF agents, Infliximab
Files: 1
DOP033: Severely active Ulcerative Colitis is associated with high baseline infliximab clearance, reduced serum half-life and worse endoscopic outcomesECCO'17 Barcelona
Year: 2017
Authors: Vande Casteele N.
Theraputic drug monitoring, Anti-TNF agents, Infliximab, Pharmacokinetics, Treat to target
Files: 1
DOP035: High gammaglobulin and low albumin serum levels independently predict secondary loss of response to anti-TNFα therapy in IBDECCO'17 Barcelona
Year: 2017
Authors: Schoenefuss F.
Therapeutic drug monitoring, Anti-TNF agents, Adalimumab, Infliximab
Files: 1
DOP036: The therapeutic efficacy of anti-TNF requires Fc-gamma receptors and can be improved by antibody hypo-fucosylationECCO'17 Barcelona
Year: 2017
Authors: Bloemendaal F.
Anti-TNF agents, Immunology, Macrophage
Files: 1
DOP037: A model for prediction of early surgery and complications in paediatric Crohn’s Disease; Results of the prospective GROWTH CD studyECCO'17 Barcelona
Year: 2017
Authors: Levine A.
paediatric, post operative complications, digestive tract damage
Files: 1
DOP039: Postoperative infectious complications in Crohn’s Disease: results from PRACTICROHN studyECCO'17 Barcelona
Year: 2017
Authors: Gutiérrez A.
Crohn's disease, Ileo caecal resection, Post operative complications
Files: 1
DOP040: Postoperative surgical recurrence in Crohn’s Disease decreases significantly in the biologic eraECCO'17 Barcelona
Year: 2017
Authors: Beelen E.
Natural history, Ileo Caecal resection, Post operative medical management, Anti-TNF agents
Files: 1